30results about "Platinum group organic compounds without C-metal linkages" patented technology

The invention provides a preparation method of a supramolecular anti-cancer drug (dicycloplatin). The preparation method comprises the following steps of: adding carboplatin and 1,1-cyclobutanedicarboxylic acid into water according to the mol ratio of 1:1, dissolving and uniformly mixing to obtain the mixed solution, and standing the mixed solution in a dark place at the temperature of more than 0 DEG C and less than or equal to 60 DEG C for 3-9 days, and concentrating under reduced pressure or freeze-drying so as to obtain dicycloplatin. The preparation method disclosed by the invention is moderate in condition and environment friendly; both the yield and the purity of dicycloplatin can be up to nearly 100%; the batch yield can reach 1000g; and thus, the preparation method is particularly applied to industrial production.

The present invention discloses an iridium complexes and the organic EL device employing the iridium complexes as light emitting guest of emitting layer can display good performance like as lower driving voltage and power consumption, increasing efficiency and half-life time. Additional, the present invention provide the suitable emitting host (H1 to H6) to collocate with the energy level of iridium complexes for the present invention. Also provided a novel preparation method to synthesize the novel ligand such as 6-bromo-3,3-dimethyl-1-phenyl-1,3-dihydroindeno[2,1-b]carbazole.

A metal complex dye having a structure defined by general formula (1) and having either 1 or 2 acid groups. [In general formula (1), A and C have a structure represented by general formula (2), and can be the same as or different to one another. B represents a linking group, and n represents an integer not less than 1. The bond between A and B and the bond between B and C can each be at least bivalent. Additionally, a double bond may be included so as to maintain the resonance structure of the compound. In general formula (2), R1-R8 each independently represents a hydrogen atom, a substituent group, or the bond with B in general formula (1). Among R1-R8, those components which are bonded in the same pyrrole ring can be bonded directly or via another base, and have a cyclic structure. X represents a carbon atom or a nitrogen atom. M represents two hydrogen atoms, two metal atoms or metal oxides, or, one metal atom or metal oxide].

Disclosed is a novel catalyst having amine ligands for synthesizing methanol or its precursor. When the catalyst is allowed to react with an alkane in the presence of an acid, at least one C—H bond of the alkane is catalytically oxidized. Therefore, the catalyst is suitable for use in forming an alkyl ester from an alkane.

A chiral catalyst is disclosed together with methods of using it for enantioselective syntheses. The chiral catalyst includes a nucleus with two metal atoms that has four bridging ligands oriented radially to the axis of the nucleus. Each of these ligands includes a two complexing atoms each complexed to one of the metal atoms. At least one of the bridging ligands includes a chiral center which is bonded to one of the complexing atoms. Preferably, all four of the bridging ligands include a chiral center bonded to one of the complexing atoms. The catalyst of the invention has been found to be useful in catalyzing carbenoid transformation reactions such as cyclopropanation.

Disclosed are compound having the structure of formula (I):

wherein M is Pt, Pd or Ni; Q is As, Sb or Bi; Z¹ is N; Z² is O or S; L¹ and L² are independently C(O), C—R¹ or C—R²; X is a Lewis base and Y¹ and Y² are independently oxygen- or sulfur-containing substituents, conjugates containing compounds of formula (I) and their use as chemotherapy agents.

The invention discloses an industrial production method of miriplatin. The method comprises the following steps: dropwise adding an aqueous solution of cis-dinitric acid[(1R,2R)-1,2-diaminocyclohexane-dihydrate]paltinum (II) into a substrate solution containing myristic acid, alkali metal hydroxide and water, stirring and reacting for 8-36 h at 40-80 DEG C after dropwise adding, adding alkyl alcohol as a disperse solvent during aftertreatment, stirring and dispersing at 20-80 DEG C for 0.5-3 h, and filtering to obtain miriplatin, wherein the alkali metal hydroxide is sodium hydroxide, potassium hydroxide or ammonium hydroxide, and the alkyl sulfhydrate is methanol, ethanol, isopropanol or n-butanol. According to the preparation method, haloalkanes such as chloroform, etc. are not used as a reaction solvent; the reaction is simple to operate by a reverse dripping method; the aftertreatment is simpler by using alkyl alcohol added after the reaction as a disperse solvent; and the miriplatin prepared by the above method has high quality, is low-cost and is easier for large-scale industrial production.

A drug containing a metal-salen complex compound which is effective for a brain tumor is provided. The present invention is an anti-brain-tumor drug containing a metal-salen complex compound represented by the following Chemical Formula (I). In the formula, M represents a metal atom which is Fe, Cr, Mn, Co, Ni, Mo, Ru, Rh, Pd, W, Re, Os, Ir, Pt, Nd, Sm, Eu, or Gd, and X represents a halogen atom.

The present invention is in relation to the fields of nanotechnology and cancer therapeutics. In particular, the present disclosure relates to improved methods for preparing lipid- conjugated platinumcompounds with high purity and good yields. The present disclosure also relates to nanoparticles comprising lipid-conjugated platinum compounds with high drug loading efficiency for use in chemotherapy, and to methods for producing said nanoparticles.

The present invention relates to the compositions containing dicycloplatin, pharmaceutical use of the compositions in the treatment and/or prevention of pain, inflammation and virus-related diseases, and methods of preparing the compostions thereof.

Disclosed herein are conjugates that include a ligand, and a compound having the structure of formula (I)

M is Pt, Pd or Ni; Q is As, Sb or Bi; Z¹ is N; Z² is O or S; L¹ and L² are independently C(O), C—R¹ or C—R²; X is a Lewis base; Y¹ and Y² are independently selected from —OR³, —OR⁴, —SR³ and —SR⁴, wherein R¹ and R² are independently selected from hydrogen, halogen, cyano, keto, ester, ether, thiol, thioether, thioester, imino, C₁-C₁₀ alkyl, C₁-C₁₀ alkenyl, alkynyl, alkoxyl, amino, amidyl, immino, sulfonyl, sulfoxyl, phosphoryl, phosphoryl ester, glycosyl, aryl, C₃-C₁₅ cycloalkyl, heteroaryl, and C₃-C₁₅ heterocycloalkyl; and R³ and R⁴ are independently selected from hydrogen, C₁-C₁₀ alkyl, C₁-C₁₀ alkenyl, alkynyl, alkoxyl, amino, amidyl, immino, sulfonyl, sulfoxyl, phosphoryl, phosphoryl ester, glycosyl, aryl, C₃-C₁₅ cycloalkyl, heteroaryl, and C₃-C₁₅ heterocycloalkyl.

The invention discloses a method for preparing oxaliplatin. The method comprises the following steps: I, performing reaction on tertpotassium chloroplatinite, potassium iodide and (1R,2R)-cyclohexanediamine to prepare diiododiam mineplatinumg; II, performing reaction on diiododiam mineplatinum obtained in the step I, and cuprous nitrate so as to obtain a nitrate middle body of amine platinum; and III, performing reaction on the nitrate middle body of the step II and sodium oxalate, thereby preparing oxaliplatin. By adopting the method, the production cost can be reduced, the medical expense of patients is reduced, the side effect is alleviated, and the yield is relatively high.

The present invention relates to a new compound for visualizing DNA-platinum crosslink, and its use as a research tool and in screening method for identifying candidate drug to be used in combination with platinating compounds such as cisplatin, carboplatin, and oxaliplatin. The project leading to this application has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No [647973]).